RCT: Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure - results from the RELAX trial

Source: JAMA Area: News According to research presented at the American College of Cardiology's Annual Scientific Session and published early online in the Journal of the American Medical Association, among patients with heart failure with preserved ejection fraction (HFPEF), phosphodiesterase-5 inhibition with administration of sildenafil for 24 weeks, did not result in significant improvement in exercise capacity or clinical status.   Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in HFPEF. Researchers therefore conducted a study to determine the effect of the phosphodiesterase-5 inhibitor sildenafil compared with placebo on exercise capacity and clinical status in HFPEF.   The multicentre, double-blind, placebo-controlled, parallel-group study involved 216 stable outpatients with HF, ejection fraction ?50%, elevated N-terminal brain-type natriuretic peptide or elevated ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news